Treatment Patterns, and Treatment
Outcomes Before and After Humulin R U500 Initiation and Device Switch Among
Type 2 Diabetes Patients in the United
States Treated with a Total Daily Dose of ≤
200 Units of Insulins per Day (U-500R Lower
Dose Cohort)

First published: 05/11/2019 Last updated: 02/04/2024





### Administrative details

**EU PAS number** 

**EUPAS32169** 

Study ID

39152

**DARWIN EU® study** 

No

# Study countries United States

#### **Study description**

The study is a retrospective real-world study using Veteran Health

Administration database to evaluate treatment patterns and treatment
outcomes before and after U-500R exposure among T2DM patients who utilized
less ≤200 units/day of insulins either before or after U-500R exposure

#### **Study status**

Finalised

### Research institutions and networks

### Institutions

### Eli Lilly and Company

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

### Contact details

### **Study institution contact**

Jieling Chen chen\_jieling@lilly.com

**Study contact** 

#### chen jieling@lilly.com

# **Primary lead investigator**Jieling Chen

**Primary lead investigator** 

# Study timelines

#### Date when funding contract was signed

Planned: 09/09/2019 Actual: 09/09/2019

#### Study start date

Planned: 11/11/2019 Actual: 15/11/2019

### Data analysis start date

Planned: 29/11/2019

#### **Date of final study report**

Planned: 31/12/2019 Actual: 05/01/2021

# Sources of funding

Pharmaceutical company and other private sector

### More details on funding

Eli Lilly and Company

# Study protocol

SIMR\_Eli Lilly\_Protocol lower-Dose\_VHA\_Final.pdf (784.62 KB)

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

# Study type

# Study type list

### **Study topic:**

Human medicinal product

Disease /health condition

#### Study type:

Non-interventional study

### Scope of the study:

Drug utilisation

#### **Data collection methods:**

Secondary use of data

#### Main study objective:

To understand the treatment pattern and outcomes before and after U-500R exposure among those who utilized <=200 units of insulin either before or after U-500R exposure

# Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

**Study drug International non-proprietary name (INN) or common name** INSULIN

#### Medical condition to be studied

Type 2 diabetes mellitus

### Population studied

#### Short description of the study population

Type 2 diabetes mellitus (T2DM) patients who utilized less ≤200 units/day of insulins either before or after U-500R exposure.

Patient Selection Criteria for the U-500R Syringe Initiators:

Inclusion criteria Patient will be included in this cohort if they: □ had ≥1 prescription claim for U-500R vial during the identification period (01JAN2014-30JUN2017), with the first prescription claim for U-500R vial designated as Index Event a (U-500R syringe initiation), and the date designated as the index date; □ had ≥2 claims with an ICD-9/10-CM code (Appendix 1) for T2DM in any position (primary/secondary) at any time prior to the index date  $\Box$  were aged ≥18 years on the index date; ☐ had continuous health plan enrollment with medical and pharmacy benefits for ≥9 months pre- and post-index event; ☐ had ≥1 prescription claim for any insulin other than U-500R in the 9-month pre-index period; ☐ had ≥1 HbA1c measurement within 90 days pre-index or 30 days post-index event; ☐ had ≥1 HbA1c measurement after the 30-day post-index period at any time in the 9-month follow-up period; and Exclusion criteria Patient will be excluded in this cohort if they: ☐ had both T1DM and T2DM, had no oral anti-diabetic drug (OADs; Appendix 1) other than metformin, with the ratio between the number of T1DM and T2DM claims > 0.5 at any time in the study period (01APR2013-31MAR2018). ☐ had previous use of U-500R in the 9-month pre-index period; □ had ≥1 claim with an ICD-9/10-CM code (Appendix 1) for secondary diabetes, gestational diabetes, diabetes complicating pregnancy, childbirth, puerperium, or nonclinical diabetes at any time during the 9-month pre-index period; ☐ had claims indicating pump use (Appendix 2) in the 9-month post-index (follow-up) period; ☐ had claims indicating TDD above 2000 units/day at any time in the pre-index

| or postindex periods; or   |
|--|
| ☐ had TDD >200 units/day both in the pre- and post-index periods               |
| Patient Selection Criteria for U-500R Kwikpen Initiators:                      |
| Inclusion criteria   |
| Patient will be included in this cohort if they:                               |
| □ had ≥1 prescription claim for U-500R Kwikpen administration during the       |
| identification period (01JAN2014-30JUN2017), with the first prescription claim |
| for  |
| U-500R Kwikpen administration designated as Index Event b, and the date        |
| designated as the index date;  |
| ☐ had ≥2 claims with an ICD-9/10-CM code (Appendix 1) for T2DM in any          |
| position (primary/secondary) at any time prior to the index date;              |
| □ were aged ≥18 years on the index date;                                       |
| ☐ had continuous health plan enrolment with medical and pharmacy benefits      |
| for ≥9 months pre- and post-index event;                                       |
| ☐ had ≥1 prescription claim for any insulin other than U-500R (Table 1) in the |
| 9-month pre-index period;  |
| ☐ had ≥1 HbA1c measurement within 90 days pre-index or 30 days post-index      |
| event; and   |
| ☐ had ≥1 HbA1c measurement after the 30-day post-index period at any time      |
| in the 9-month post-index period.  |
| Exclusion criteria   |
| Patient will be excluded in this cohort if they:                               |
| ☐ had both T1DM and T2DM, had no OADs (Appendix 1) other than metformin,       |
| with   |
| the ratio between the number of T1DM and T2DM claims >0.5 at any time in       |
| the study  |
| period (01APR2013-31MAR2018);  |

|     | lead manifestation and IL FOOD in the Organith was indeed a said of           |  |  |  |
|-----|---|--|--|--|
|     | had previous use of U-500R in the 9-month pre-index period;                   |  |  |  |
|     | had ≥1 claim with an ICD-9/10-CM code (Appendix 1) for secondary diabetes     |  |  |  |
| ge  | estational diabetes, diabetes complicating pregnancy, childbirth, puerperium, |  |  |  |
| or  | nonclinical diabetes at any time during the 9-month pre-index period;         |  |  |  |
|     | had evidence of pump use (Appendix 2) in the 9-month post-index period;       |  |  |  |
|     | had claims indicating TDD above 2000 units/day at any time in the pre-index   |  |  |  |
| or  | postindex periods; or   |  |  |  |
|     | had TDD >200 units/day in the 9 months pre- and post-index periods.           |  |  |  |
| Pa  | tient Selection Criteria for any U-500R Initiators:                           |  |  |  |
| Ind | clusion criteria  |  |  |  |
| Pa  | tient will be included in this cohort if they:                                |  |  |  |
|     | had ≥1 prescription claim for U-500R syringe/Kwikpen administration during    |  |  |  |
| th  | e identification period (01JAN2014-30JUN2017), with the first prescription    |  |  |  |
| cla | aim for U-500R syringe or Kwikpen administration designated as Index Event    |  |  |  |
| С,  | and the date designated as the index date;                                    |  |  |  |
|     | had ≥2 claims with an ICD-9/10-CM code (Appendix 1) for T2DM in any           |  |  |  |
| ро  | sition (primary/secondary) at any time prior to the index date;               |  |  |  |
|     | were aged ≥18 years on the index date;  |  |  |  |
|     | had continuous health plan enrollment with medical and pharmacy benefits      |  |  |  |
| fo  | r ≥9 months pre- and post-index event;  |  |  |  |
|     | had ≥1 prescription claim for any insulin other than U-500R (Table 1) in the  |  |  |  |
| 9-  | month pre-index period;   |  |  |  |
|     | had ≥1 HbA1c measurement within 90 days pre-index or 30 days post-index       |  |  |  |
| ev  | vent; and   |  |  |  |
|     | had ≥1 HbA1c measurement after the 30-day post-index period at any time       |  |  |  |
| in  | the 9-month post-index period.  |  |  |  |
| Ex  | clusion criteria  |  |  |  |
| Pa  | Patient will be excluded in this cohort if they:                              |  |  |  |

| ☐ had both T1DM and T2DM, had no OADs (Appendix 1) other than metformin,                    |  |  |  |
|---|--|--|--|
| with the ratio between the number of T1DM and T2DM claims $>$ 0.5 at any time               |  |  |  |
| in the study period (01APR2013-31MAR2018);  |  |  |  |
| ☐ had previous use of U-500R in the 9-month pre-index period;                               |  |  |  |
| □ had ≥1 claim with an ICD-9/10-CM code (Appendix 1) for secondary diabetes,                |  |  |  |
| gestational diabetes, diabetes complicating pregnancy, childbirth, puerperium,              |  |  |  |
| or nonclinical diabetes at any time during the 9-month pre-index period;                    |  |  |  |
| ☐ had evidence of pump use (Appendix 2) in the 9-month post-index period;                   |  |  |  |
| $\hfill\square$ had claims indicating TDD above 2000 units/day at any time in the pre-index |  |  |  |
| or postindex periods; or  |  |  |  |
| $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $  |  |  |  |
| Patient Selection Criteria for U-500R Device Switchers from Syringe to Kwikpen              |  |  |  |
| Inclusion criteria  |  |  |  |
| Patient will be included in this cohort if they:  |  |  |  |
| ☐ had ≥1 claim for U-500R Kwikpen administration in the identification period               |  |  |  |
| (01JAN2014-30JUN2017), with the first prescription claim for U-500R Kwikpen                 |  |  |  |
| administration designated as Index Event 2, and the date designated as the                  |  |  |  |
| index date;   |  |  |  |
| □ had ≥2 claims with an ICD-9/10-CM code (Appendix 1) for T2DM in any                       |  |  |  |
| position (primary/secondary) at any time prior to the index date;                           |  |  |  |
| □ were aged ≥18 years on the index date;  |  |  |  |
| ☐ had continuous health plan enrollment with medical and pharmacy benefits                  |  |  |  |
| for ≥9 months pre- and post-index event;  |  |  |  |
| □ had ≥1 prescription claim for U-500R vial use in the 9-month pre-index                    |  |  |  |
| period;   |  |  |  |
| $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $  |  |  |  |
| index event; and  |  |  |  |
| □ had ≥1 HbA1c measurement after the 30-day post-index period.                              |  |  |  |
| Exclusion criteria  |  |  |  |

| Patient will be excluded in this cohort if they:                               |
|--|
| ☐ had both T1DM and T2DM, had no OADs (Appendix 1) other than metformin,       |
| with the ratio between the number of T1DM and T2DM claims >0.5 at any time     |
| in the study period (01APR2013-31MAR2018);                                     |
| had previous use of U-500R Kwikpen administration in the 9-month pre-index     |
| period;  |
| □ had ≥1 claim with an ICD-9/10-CM code (Appendix 1) for secondary diabetes,   |
| gestational diabetes, diabetes complicating pregnancy, childbirth, puerperium, |
| or nonclinical diabetes at any time during the 9-month pre-index period;       |
| ☐ had claims indicating pump use (Appendix 2) in the 9-month post-index        |
| period;  |
| ☐ had claims indicating TDD exceeding 2000 units/day at any time in the pre-   |
| index or post-index periods; or  |
| □ had TDD >200 units/day in the pre- and post-index periods.                   |
| Age groups   |
| Adults (18 to < 46 years)  |
| Adults (46 to < 65 years)  |
| Adults (65 to < 75 years)  |
| Adults (75 to < 85 years)  |
| Adults (85 years and over)   |
| Special population of interest   |
| Other  |
| Special population of interest, other  |
| Type 2 diabetes mellitus patients  |
|  |

### Estimated number of subjects

1200

# Study design details

#### **Outcomes**

Treatment Patterns and HbA1c, Hypoglycemia

#### Data analysis plan

This will be a retrospective cohort study using the Veterans Health Administration (VHA) database. 1. The first prescription claim date for U-500R syringe or U-500R Kwikpen administration will be considered U-500R initiation and designated as Index Event 1 (syringe: Index Event 1a, Kwikpen: Index Event 1b, any U-500R use: Index Event 1c). 2. The date for U-500R device switch from syringe to Kwikpen will be designated as Index Event 2. 3. The study period will range from 01APR2013–31MAR2018. 4. The identification period will be 01JAN2014–30JUN2017, the pre-index and post-index (follow-up) periods will be 9 months, respectively

### **Documents**

#### Study results

EUPAS32169-39150.pdf (4.68 MB)

# Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

#### Data sources (types)

Administrative healthcare records (e.g., claims)

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

#### **Data characterisation conducted**

No